Professional Essentials · Free · No registration
Pain & fatigue beyond inflammation
Distinguishing fibromyalgia, ME/CFS, orthostatic intolerance and overlapping disease while building a practical care plan.
Persistent pain and fatigue require a positive clinical formulation. Fibromyalgia, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), autonomic disorders and local musculoskeletal or neurological conditions may mimic or accompany inflammatory rheumatic disease. Symptoms can be disabling despite normal routine tests. The task is to identify contributing processes, recognize consequential alternatives and match treatment to an explicit target.
1. Define the symptom and the urgency
Ask what the patient means by “weak”: low energy, sleepiness, presyncope, pain-limited effort or reproducible loss of power. Establish onset, previous function, medication changes and the response to physical and cognitive activity. Examine joints, strength, neurological findings and relevant organ systems; obtain orthostatic measurements when the history suggests them.
New focal neurological deficits, rapidly progressive weakness, severe cardiopulmonary symptoms, syncope with concerning features or inability to maintain hydration require prompt assessment. Persistent fever, weight loss, objective synovitis or organ abnormalities should redirect the investigation. Neither a prior fibromyalgia diagnosis nor a normal inflammatory marker excludes a second disease.
The CDC evaluation resource, updated April 2026, supports sequencing tests according to presentation. Blood count, chemistry, thyroid function and selected iron studies may clarify common contributors. Assess sleep disorders and medication burden. Order autoantibodies, imaging or neuromuscular investigations for a defined clinical question; repeated broad screening creates incidental findings without necessarily improving care.
Pain, fatigue, sleepiness or weakness? → Open demo · No registration
2. Recognize fibromyalgia without closing the differential
Fibromyalgia combines generalized pain with variable fatigue, nonrestorative sleep and cognitive symptoms. The 2016 criteria use pain distribution, symptom severity and duration, including generalized pain in at least four of five regions and symptoms generally present for at least three months. A questionnaire supports assessment; it cannot replace clinical examination or explain every new symptom.
Fibromyalgia can coexist with inflammatory arthritis, osteoarthritis, neuropathy or another illness. Separate pain-related tenderness from swollen joints, tissue damage and objective inflammatory findings. In established rheumatic disease, a high symptom score may reflect several mechanisms; escalation of immunosuppression should address demonstrated disease activity rather than pain intensity alone.
The 2025 HAS guideline emphasizes a coordinated, individualized approach. Explain the diagnosis without implying imaginary symptoms. Agree on achievable goals, examine sleep and functional barriers, and coordinate symptom care with the team best placed to deliver it.
Applying fibromyalgia criteria → Open demo · No registration
3. Identify post-exertional malaise before prescribing activity
Post-exertional malaise (PEM) is disproportionate worsening after exertion, often delayed and prolonged. Ask about the following day, recovery time, cognitive work and sensory demands, not only immediate exercise tolerance. A patient may appear relatively well during a short visit yet have substantial loss of function afterward.
NAM/IOM criteria require prolonged reduction in activity with fatigue, PEM and unrefreshing sleep, plus cognitive impairment or orthostatic intolerance. Their duration requirement exceeds six months. NICE NG206 uses a different symptom framework and permits diagnosis after three months. State which framework is being applied; do not combine selected elements into a new rule.
For ME/CFS, NICE advises against fixed incremental exercise programs and exercise presented as a cure. Energy management should accommodate fluctuating capacity and prevent repeated crashes. Support movement, positioning and participation within tolerance. Cognitive behavioral therapy may help coping if wanted; it is not a treatment for supposedly mistaken illness beliefs. Fibromyalgia exercise recommendations must be adapted when PEM coexists.
PEM and an individualized activity plan → Open demo · No registration ME/CFS diagnostic frameworks → Professional access required
4. Assess the overlapping pathway
Orthostatic symptoms warrant evaluation of pulse and blood pressure with a consistent standing or tilt protocol. Canadian Cardiovascular Society guidance requires a coherent chronic orthostatic syndrome for POTS, not an isolated heart-rate spike. Consider dehydration, anemia, thyroid disease, medications and other explanations. Compression, fluid/salt strategies and selected medicines depend on phenotype and comorbidities; generic volume expansion can be inappropriate in kidney or heart disease.
Burning pain, sensory loss, asymmetry or objective weakness can justify neurological assessment. Regional autonomic and trophic changes raise a different question from generalized pain. Hypermobility-related instability needs a functional and connective-tissue assessment; a flexibility score alone does not establish hypermobile Ehlers–Danlos syndrome. New objective findings deserve their own evaluation even when several diagnoses already coexist.
Long COVID can include PEM, autonomic dysfunction, pain or specific organ disease. Treat the demonstrated problem and avoid transferring evidence between unlike phenotypes. Pediatric amplified pain requires an age-appropriate multidisciplinary pathway, with reassessment when the clinical pattern or response to rehabilitation is unexpected.
5. Choose treatment with measurable value
For fibromyalgia without PEM, EULAR recommendations strongly support exercise, individualized to ability and preference. Education, sleep care, psychological therapies and selected medication can complement it. Start at a sustainable level and review function, symptoms and adverse effects. Treatment should improve a meaningful activity, not merely produce a temporary numerical change.
U.S. approved adult options include duloxetine, milnacipran, pregabalin and sublingual cyclobenzaprine, Tonmya. The Tonmya approval concerns a specific formulation and regimen; it does not automatically transfer to swallowed generic cyclobenzaprine. Match the drug to symptoms, interactions, organ function and sedation risk. Review pregnancy-related precautions and avoid unnecessary serotonergic or sedative combinations.
Strong opioids or repeated glucocorticoid courses are poor default strategies for isolated fibromyalgia. Experimental immune or regenerative therapies need indication-specific controlled evidence. The randomized rituximab trial in ME/CFS did not establish benefit. A plausible immune mechanism, a positive commercial biomarker or disappointment with prior care does not alone justify immune depletion.
Medication selection and newer evidence → Professional access required
6. Make the care pathway explicit
Document the working diagnosis, supporting findings, uncertainties and who reviews outstanding results. The next coordinator may be primary care, rehabilitation, a pain service, neurology, sleep medicine or an experienced ME/CFS team. Rheumatology continues appropriate care for an established inflammatory disorder; a consultation for non-inflammatory symptoms should end with an actionable handoff.
Track function, symptom targets, delayed crashes and medication burden. Distinguish an adequate unsuccessful trial from intolerance, unaffordability or a plan the patient could not implement. Simplify ineffective treatment safely and reopen the differential when objective findings change.
Choose one or two review outcomes that the patient can track without excessive effort: completing personal care, tolerating a necessary appointment, sleeping with fewer interruptions or reducing the frequency of crashes. Ask what changed after each intervention, including the subsequent days. Improvement in one domain can coexist with persistent limitation in another; that distinction helps decide whether to continue, modify or stop treatment.
For severe illness, adapt visit duration, transport and sensory exposure. Review nutrition, hydration, self-care, immobility complications and caregiver needs. A plan that requires more capacity than the patient has is unlikely to succeed. Agree on accessible follow-up and a small set of clear reasons for earlier reassessment.
Clinical handoff and follow-up responsibilities → Professional access required
Selected sources
- Wolfe et al. Revised fibromyalgia diagnostic criteria, 2016.
- HAS: Fibromyalgia in adults, 2025.
- CDC: Evaluation of ME/CFS, April 17, 2026.
- CDC: NAM/IOM diagnostic criteria for ME/CFS.
- NICE NG206: ME/CFS diagnosis and management.
- Canadian Cardiovascular Society POTS position statement, 2020.
- EULAR revised fibromyalgia recommendations, 2016.
- FDA: Tonmya prescribing information, 2025.
- Fluge et al. Rituximab in ME/CFS randomized trial, 2019.